SAN DIEGO – Conduit Pharmaceuticals Inc. (NASDAQ:CDT), a pharmaceutical preparations company, has announced the date for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for October 2, 2024, with a record date of August 20, 2024, for determining stockholders entitled to vote at the meeting.
Conduit Pharmaceuticals, previously known as Murphy Canyon Acquisition Corp., is headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, California, and operates under the leadership of CEO Dr. David Tapolczay. The company is incorporated in Delaware and has its fiscal year end on December 31.
The company's common stock and redeemable warrants are traded on The Nasdaq Stock Market under the symbols CDT and CDTTW, respectively. The warrants are exercisable for one share of common stock at an exercise price of $11.50.
InvestingPro Insights
As Conduit Pharmaceuticals Inc. (NASDAQ:CDT) gears up for its 2024 Annual Meeting of Stockholders, a glance at the company's financial health and stock performance through InvestingPro data and tips provides a broader context for investors. With a market cap of $78.26 million and a concerning P/E ratio of -24.95, the company's financials reflect challenges, including a significant negative return on assets of -97.97% over the last twelve months as of Q1 2024. The stock has faced a steep decline, with a 1-month price total return of -65.13% and a 1-year price total return of -90.08%, indicating a period of pronounced volatility for shareholders.
InvestingPro Tips highlight that the stock is currently in oversold territory according to the RSI, and has indeed taken a significant hit over the last week. Furthermore, the lack of dividend payments to shareholders may also be a consideration for those reliant on investment income. For investors looking for deeper insights and additional guidance, there are more InvestingPro Tips available, which can be accessed for Conduit Pharmaceuticals at: https://www.investing.com/pro/CDT. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, providing a wealth of knowledge for making informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.